The initial results describing the performance of the test were presented at The American Association for the Study of Liver Diseases (AASLD) Liver Meeting (Boston, MA, USA, 8–12.11.2019), included 137 patients with HCC and 313 controls and showed the overall panel sensitivity to detect HCC, at the level of 80.3% (95% CI 72.6–86.6) vs. 42.3% (95% CI 33.9–51.1) for AFP 20 ng/ml, with the specificity of 90.0% and 97.4%, respectively [44]. This evidence concerns the gene AFP and hepatocellular carcinoma.